WallStSmart

Shuttle Pharmaceuticals Inc (SHPH)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

SHPH leads profitability with a 0.0% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

SHPH

Avoid

18

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 5.0

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SHPH1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

SHPH4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.97M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : SHPH

The strongest argument for SHPH centers on Price/Book.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : SHPH

The primary concerns for SHPH are Revenue Growth, EPS Growth, Market Cap.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

SHPH profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.80 — expect wider price swings.

VTRS is growing revenue faster at 5.0% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Bottom Line

VTRS scores higher overall (50/100 vs 18/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Shuttle Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development and commercialization of drugs to sensitize cancers to radiation therapy. The company is headquartered in Rockville, Maryland.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?